Increased hyaluronan levels and decreased dendritic cell activation are associated with tumor invasion in murine lymphoma cell lines

Immunobiology

Volumn 217, Issue 9, 2012, Pages 842-850

  Cordo Russo, Rosalia I ^a   Ernst, Glenda ^a   Lompardía, Silvina ^a   Blanco, Guillermo ^a   Álvarez, Élida ^a   Garcia, Mariana G ^a,b   Hajos, Silvia ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b UNIVERSIDAD AUSTRAL   (Argentina)

Author keywords

Dendritic cells; Hyaluronan; Hyaluronan synthases; Hyaluronidases; Lymphoma

Indexed keywords

HYALURONIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; CANCER GROWTH; CANCER INFILTRATION; CANCER INVASION; CANCER MODEL; CELL ACTIVATION; CONTROLLED STUDY; DENDRITIC CELL; DISEASE ACTIVITY; HYALURONIC ACID BLOOD LEVEL; IMMUNE RESPONSE; LIVER METASTASIS; LYMPH NODE METASTASIS; LYMPHOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS;

ANIMALS; CELL LINE, TUMOR; DENDRITIC CELLS; GLUCURONOSYLTRANSFERASE; HYALURONIC ACID; HYALURONOGLUCOSAMINIDASE; LYMPHOMA; MICE; MICE, INBRED BALB C; NEOPLASM INVASIVENESS;

EID: 84864303917     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2011.12.006     Document Type: Article

References (54)

1. Alaniz L., Rizzo M., Malvicini M., Jaunarena J., Avella D., Atorrasagasti C., Aquino J.B., Garcia M., Matar P., Silva M., Mazzolini G. Low molecular weight hyaluronan inhibits colorectal carcinoma growth by decreasing tumor cell proliferation and stimulating immune response. Cancer Lett. 2009, 278(1):9-16.
2. Ambe K., Mori M., Enjoji M. S-100 protein-positive dendritic cells in colorectal adenocarcinomas. Distribution and relation to the clinical prognosis. Cancer 1989, 63(3):496-503.
3. Bertrand P., Courel M.N., Maingonnat C., Jardin F., Tilly H., Bastard C. Expression of HYAL2 mRNA, hyaluronan and hyaluronidase in B-cell non-Hodgkin lymphoma: relationship with tumor aggressiveness. Int. J. Cancer 2005, 113(2):207-212.
4. Bourguignon L.Y.W., Gilad E., Peyrollier K. Heregulin-mediated ErbB2-ERk signaling activates hyaluronan synthases leading to CD44-dependent ovarian tumor cell growth and migration. J. Biol. Chem. 2007, 282(27):19426-19441.
5. Bullard K.M., Kim H.R., Wheeler M.A., Wilson C.M., Neudauer C.L., Simpson M.A., McCarthy J.B. Hyaluronan synthase-3 is upregulated in metastatic colon carcinoma cells and manipulation of expression alters matrix retention and cellular growth. Int. J. Cancer 2003, 107(5):739-746.
6. Burchardt E.R., Hein R., Bosserhoff A.K. Laminin, hyaluronan, tenascin-C and type VI collagen levels in sera from patients with malignant melanoma. Clin. Exp. Dermatol. 2003, 28(5):515-520.
7. Calabro L., Musolino C., Spatari G., Vinci R., Calatroni A. Increased concentration of circulating acid glycosaminoglycans in chronic lymphocytic leukaemia and essential thrombocythaemia. Clin. Chim. Acta 1998, 269(2):185-199.
8. Coquerelle C., Moser M. DC subsets in positive and negative regulation of immunity. Immunol. Rev. 2010, 234(1):317-334.
9. Cordo-Russo R., Garcia M.G., Barrientos G., Orsal A.S., Viola M., Moschansky P., Ringel F., Passi A., Alaniz L., Hajos S., Blois S.M. Murine abortion is associated with enhanced hyaluronan expression and abnormal localization at the fetomaternal interface. Placenta 2009, 30(1):88-95.
10. Cordo-Russo R.I., Alaniz L.D., Saccodossi N., Lompardia S., Blanco G., Alvarez E., Garcia M.G., Hajos S.E. Hyaluronan induces migration of multidrug-resistant lymphoma cell lines in vitro through Tiam1 activation by a PI3K-dependent mechanism. Leuk. Res. 2010, 34(11):1525-1532.
11. Chaput N., Conforti R., Viaud S., Spatz A., Zitvogel L. The Janus face of dendritic cells in cancer. Oncogene 2008, 27(45):5920-5931.
12. Christofori G. New signals from the invasive front. Nature 2006, 441(7092):444-450.
13. Dahl I.M., Turesson I., Holmberg E., Lilja K. Serum hyaluronan in patients with multiple myeloma: correlation with survival and Ig concentration. Blood 1999, 93(12):4144-4148.
14. Delpech B., Chevallier B., Reinhardt N., Julien J.P., Duval C., Maingonnat C., Bastit P., Asselain B. Serum hyaluronan (hyaluronic acid) in breast cancer patients. Int. J. Cancer 1990, 46(3):388-390.
15. Eisenthal A., Polyvkin N., Bramante-Schreiber L., Misonznik F., Hassner A., Lifschitz-Mercer B. Expression of dendritic cells in ovarian tumors correlates with clinical outcome in patients with ovarian cancer. Hum. Pathol. 2001, 32(8):803-807.
16. Fiore F., Von Bergwelt-Baildon M.S., Drebber U., Beyer M., Popov A., Manzke O., Wickenhauser C., Baldus S.E., Schultze J.L. Dendritic cells are significantly reduced in non-Hodgkin's lymphoma and express less CCR7 and CD62L. Leuk. Lymphoma 2006, 47(4):613-622.
17. Ghatak S., Misra S., Toole B. Hyaluronan oligosaccharides inhibit anchorage-independent growth of tumor cells by suppressing the phosphoinositide 3-kinase/Akt cell survival pathway. J. Biol. Chem. 2002, 277:38013-38020.
18. Hasselbalch H., Hovgaard D., Nissen N., Junker P. Serum hyaluronan is increased in malignant lymphoma. Am. J. Hematol. 1995, 50(4):231-233.
19. Hautmann S.H., Schroeder G.L., Civantos F., Duncan R.C., Gnann R., Friedrich M.G., Hellstern A., Huland H., Soloway M.S., Lokeshwar V.B. Hyaluronic acid and hyaluronidase. 2 new bladder carcinoma markers. Urologe A 2001, 40(2):121-126.
20. Heldin P., Karousou E., Skandallis S.S. Growth factor regulation of hyaluronan deposition in malignancies. Hyaluronan in Cancer Biology 2009, vol. 37. Academic Press/Elsevier, San Diego, CA.
21. Hiltunen E., Anttila M., Kultti A., Ropponen K., Penttinen J., Yliskoski M., Kuronen A., Juhola M., Tammi R., Tammi M., Kosma V. Elevated hyaluronan concentration without hyaluronidase activation in malignant epithelial ovarian tumors. Cancer Res. 2002, 62:6410-6413.
22. Hussin H.N., Zulkifli F.N., Phang K.S., Cheong S.K. Dendritic cell distribution in lymphomas. Malays. J. Pathol. 2009, 31(2):105-112.
23. Itano N., Kimata K. Altered hyaluronan biosynthesis in cancer progression. Semin. Cancer Biol. 2008, 18(4):268-274.
24. Iwamoto M., Shinohara H., Miyamoto A., Okuzawa M., Mabuchi H., Nohara T., Gon G., Toyoda M., Tanigawa N. Prognostic value of tumor-infiltrating dendritic cells expressing CD83 in human breast carcinomas. Int. J. Cancer 2003, 104(1):92-97.
25. Jacobson A., Rahmanian M., Rubin K., Heldin P. Expression of hyaluronan synthase 2 or hyaluronidase 1 differentially affect the growth rate of transplantable colon carcinoma cell tumors. Int. J. Cancer 2002, 102(3):212-219.
26. Jiang D., Liang J., Noble P.W. Hyaluronan in tissue injury and repair. Annu. Rev. Cell Dev. Biol. 2007, 23:435-461.
27. Johnson P., Ruffell B. CD44 and its role in inflammation and inflammatory diseases. Inflamm. Allergy Drug Targets 2009, 8(3):208-220.
28. Joyce J.A., Pollard J.W. Microenvironmental regulation of metastasis. Nat. Rev. Cancer 2009, 9(4):239-252.
29. Kuang D.M., Zhao Q., Xu J., Yun J.P., Wu C., Zheng L. Tumor-educated tolerogenic dendritic cells induce CD3epsilon down-regulation and apoptosis of T cells through oxygen-dependent pathways. J. Immunol. 2008, 181(5):3089-3098.
30. Kultti A., Pasonen-Seppänen S., Jauhiainen M., Rilla K.J., Kärnä R., Pyöriä E., Tammi R.H., Tammi M.I. 4-Methylumbelliferone inhibits hyaluronan synthesis by depletion of cellular UDP-glucuronic acid and downregulation of hyaluronan synthase 2 and 3. Exp. Cell Res. 2009, 315(11):1914-1923.
31. Kuwabara H., Yoneda M., Nagai M., Nishio H., Tasaka T., Suzuki K., Mori H. High levels of hyaluronan production by a malignant lymphoma cell line with primary effusion lymphoma immunophenotype OHK. Br. J. Haematol. 2003, 120(6):1055-1057.
32. Lai E., Singh R., Teng B., Zhao Y., Sharratt E., Howell G., Rajput A., Bullard Dunn K. Inhibition of hyaluronan synthase-3 decreases subcutaneous colon cancer growth in mice. Dis. Colon. Rectum. 2010, 53(4):475-482.
33. Laurent T.C., Fraser J.R. Hyaluronan. FASEB J. 1992, 6(7):2397-2404.
34. Lokeshwar V.B., Lopez L.E., Munoz D., Chi A., Shirodkar S.P., Lokeshwar S.D., Escudero D.O., Dhir N., Altman N. Antitumor activity of hyaluronic acid synthesis inhibitor 4-methylumbelliferone in prostate cancer cells. Cancer Res. 2010, 70(7):2613-2623.
35. Lokeshwar V.B., Selzer M.G. Hyaluronidase: both a tumor promoter and suppresor. Hyaluronan in Cancer Biology 2009, vol. 189. Academic Press/Elsevier, San Diego, CA.
36. Lopes E.C., Ernst G., Aulicino P., Vanzulli S., Garcia M., Alvarez E., Hajos S.E. Dissimilar invasive and metastatic behavior of vincristine and doxorubicin-resistant cell lines derived from a murine T cell lymphoid leukemia. Clin. Exp. Metast. 2002, 19(4):283-290.
37. Lopes E.C., Garcia M., Benavides F., Shen J., Conti C.J., Alvarez E., Hajos S.E. Multidrug resistance modulators PSC 833 and CsA show differential capacity to induce apoptosis in lymphoid leukemia cell lines independently of their MDR phenotype. Leuk. Res. 2003, 27(5):413-423.
38. Miele L., Forgione A., La Torre G., Vero V., Cefalo C., Racco S., Vellone V.G., Vecchio F.M., Gasbarrini G., Rapaccini G.L., Neuman M.G., Grieco A. Serum levels of hyaluronic acid and tissue metalloproteinase inhibitor-1 combined with age predict the presence of nonalcoholic steatohepatitis in a pilot cohort of subjects with nonalcoholic fatty liver disease. Transl. Res. 2009, 154(4):194-201.
39. Mohty M., Isnardon D., Vey N., Briere F., Blaise D., Olive D., Gaugler B. Low blood dendritic cells in chronic myeloid leukaemia patients correlates with loss of CD34+/CD38- primitive haematopoietic progenitors. Br. J. Haematol. 2002, 119(1):115-118.
40. Mummert M.E. Immunologic roles of hyaluronan. Immunol. Res. 2005, 31(3):189-206.
41. Orsini E., Guarini A., Chiaretti S., Mauro F.R., Foa R. The circulating dendritic cell compartment in patients with chronic lymphocytic leukemia is severely defective and unable to stimulate an effective T-cell response. Cancer Res. 2003, 63(15):4497-4506.
42. Paiva P., Damme M., Tellbach M., Jones R., Jobling T., Salamonsen L. Expression patterns of hyaluronan, hyaluronan synthases and hyaluronidases indicate a role for hyaluronan in the progression of endometrial cancer. Gynecol. Oncol. 2005, 98:193-202.
43. Schlapbach C., Ochsenbein A., Kaelin U., Hassan A.S., Hunger R.E., Yawalkar N. High numbers of DC-SIGN+ dendritic cells in lesional skin of cutaneous T-cell lymphoma. J. Am. Acad. Dermatol. 2010, 62(6):995-1004.
44. Simpson M.A., Reiland J., Burger S.R., Furcht L.T., Spicer A.P., Oegema T.R., McCarthy J.B. Hyaluronan synthase elevation in metastatic prostate carcinoma cells correlates with hyaluronan surface retention, a prerequisite for rapid adhesion to bone marrow endothelial cells. J. Biol. Chem. 2001, 276(21):17949-17957.
45. Steinman R.M., Idoyaga J. Features of the dendritic cell lineage. Immunol. Rev. 2010, 234(1):5-17.
46. Stern R. Hyaluronidases in cancer biology. Hyaluronan in Cancer Biology 2009, vol. 207. Academic Press/Elsevier, San Diego, CA.
47. Stewart T.J., Abrams S.I. How tumours escape mass destruction. Oncogene 2008, 27(45):5894-5903.
48. Tammi R.H., Kultti A., Kosma V.M., Pirinen R., Auvinen P., Tammi M.I. Hyaluronan in human tumors: importance of stromal and cancer cell-associated hyaluronan. Hyaluronan in Cancer Biology 2009, vol. 257. Academic Press/Elsevier, San Diego (CA).
49. Termeer C., Benedix F., Sleeman J., Fieber C., Voith U., Ahrens T., Miyake K., Freudenberg M., Galanos C., Simon J.C. Oligosaccharides of Hyaluronan activate dendritic cells via toll-like receptor 4. J. Exp. Med. 2002, 195(1):99-111.
50. Toole B.P. Hyaluronan: from extracellular glue to pericellular cue. Nat. Rev. Cancer 2004, 4(7):528-539.
51. Toole B.P., Slomiany M.G. Hyaluronan: a constitutive regulator of chemoresistance and malignancy in cancer cells. Semin. Cancer Biol. 2008, 18(4):244-250.
52. Udabage L., Brownlee G., Nilsson S., Brown T. The over-expression of HAS2, Hyal-2 and CD44 is implicated in the invasiveness of breast cancer. Exp. Cell Res. 2005, 310:205-217.
53. Weigel P.H., DeAngelis P.L. Hyaluronan synthases: a decade-plus of novel glycosyltransferases. J. Biol. Chem. 2007, 282(51):36777-36781.
54. Xing R.D., Chang S.M., Li J.H., Li H., Han Z.X. Serum hyaluronan levels in oral cancer patients. Chin. Med. J. (Engl.) 2008, 121(4):327-330.